A. López-Albaitero

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

S. Chandarlapaty, Y. Janjigian, E. de Stanchina, 2017, Oncoimmunology.

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients

R. Ferris, S. Ferrone, Christopher A. Lord, 2013, Clinical Cancer Research.